menu
    • menu
    [{"orgOrder":0,"company":"Louisville Metabolic and Atherosclerosis Research Center","sponsor":"Provident Clinical Research | Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cholestyramine","moa":"Bile acids","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Louisville Metabolic and Atherosclerosis Research Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Louisville Metabolic and Atherosclerosis Research Center \/ Provident Clinical Research | Daiichi Sankyo","highestDevelopmentStatusID":"11","companyTruncated":"Louisville Metabolic and Atherosclerosis Research Center \/ Provident Clinical Research | Daiichi Sankyo"},{"orgOrder":0,"company":"Louisville Metabolic and Atherosclerosis Research Center","sponsor":"Provident Clinical Research | Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cholestyramine","moa":"Bile acids","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Louisville Metabolic and Atherosclerosis Research Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Louisville Metabolic and Atherosclerosis Research Center \/ Provident Clinical Research | Daiichi Sankyo","highestDevelopmentStatusID":"11","companyTruncated":"Louisville Metabolic and Atherosclerosis Research Center \/ Provident Clinical Research | Daiichi Sankyo"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cholestyramine","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Pharmascience Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmascience Inc. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Cholestyramine

    Menu

    Cholestyramine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome

                            Details : Cholestyramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Short Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 06, 2019

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Louisville Metabolic and Atherosclerosis Research Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Louisville Metabolic and Atherosclerosis Research Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Provident Clinical Research | Daiichi Sankyo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Thr...

                            Details : Cholestyramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 13, 2010

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Provident Clinical Research | Daiichi Sankyo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Louisville Metabolic and Atherosclerosis Research Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Louisville Metabolic and Atherosclerosis Research Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Provident Clinical Research | Daiichi Sankyo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study

                            Details : Cholestyramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2010

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Provident Clinical Research | Daiichi Sankyo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth